SCHEMBL6091373

SCHEMBL6091373

COc1cc(Oc2ccc3c(c2)c(C#N)cn3C)cc(OC)c1OP(C(C)(C)C)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 6/20 0.40
IMPDH2 P12268 1/20 0.39
SRC P12931 1/20 0.37
PFKFB2 O60825 3/20 0.35
PFKFB1 P16118 3/20 0.35
PFKFB3 Q16875 3/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.34
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34
TUBB4B P68371 1/20 0.34
TUBB3 Q13509 1/20 0.34
TUBB2A Q13885 1/20 0.34
TUBB8 Q3ZCM7 1/20 0.34
TUBA3E Q6PEY2 1/20 0.34
TUBA1A Q71U36 1/20 0.34
TUBA1C Q9BQE3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6088237 0.88 SRC (0.47) ARIMPDH2SRCPFKFB2PFKFB1
SCHEMBL6090667 0.85 AR (0.46) ARIMPDH2PFKFB2PFKFB1PFKFB3
SCHEMBL6088595 0.84 AR (0.43) ARIMPDH2SRCPFKFB2PFKFB1
SCHEMBL6088602 0.81 AR (0.40) ARIMPDH2SRCPFKFB2PFKFB1
SCHEMBL1777994 0.76 IMPDH2 (0.56) IMPDH2SLC6A4ADRB2
SCHEMBL31687136 0.68 TUBB1 (0.48) SRCTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31687121 0.67 HDAC8 (0.58) IMPDH2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6087031 0.65 IMPDH2 (0.46) ARIMPDH2SRCSLC6A4
SCHEMBL5857816 0.65 AS3MT (0.55) ARSRCPFKFB2PFKFB1PFKFB3
SCHEMBL2417482 0.65 IMPDH2 (0.59) IMPDH2NPSR1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7125906-B2 Indole derivatives having anti-angiogenetic activity ASTRAZENECA AB (SE) 2006-10-24 US disclosed
US-20050159474-A1 Angiogenesis inhibitors for cardiovascular disorders, neovascularization ASTRAZENECA AB (SE) 2005-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159474-A1 Angiogenesis inhibitors for cardiovascular disorders, neovascularization FLT1, FLT4, VEGFA AR 3468/4885IMPDH2 3719/4885SRC 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.